Ptc Therapeutics, INC Form 4 insider transactions

Mark Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares of common stock on March 12, 2025, under a pre-arranged 10b5-1 trading plan.

Mark Boulding, Executive VP and CLO of PTC Therapeutics, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

Director Allan Steven Jacobson sold 1,230 shares of PTC Therapeutics (PTCT) common stock at an average price of $51.52 on March 4, 2025.

Christine Marie Utter, SVP, Chief Accounting Officer of PTC Therapeutics, reports selling shares of common stock to cover tax withholding obligations related to RSU vesting.

Pierre Gravier, CFO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

CEO Eric Pauwels sold shares of PTC Therapeutics stock to cover tax obligations arising from the vesting of restricted stock units (RSUs).

CEO Matthew Klein sold shares of PTC Therapeutics stock to cover tax obligations related to the vesting of restricted stock units.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).

CEO Eric Pauwels sold shares of PTC Therapeutics to cover tax obligations related to the vesting of restricted stock units (RSUs).

CEO Matthew B. Klein of PTC Therapeutics sold shares of common stock on January 7th and 8th, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units (RSUs).

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units (RSUs).

Director Alethia Young acquired 4,000 shares of common stock and 8,800 stock options in PTC Therapeutics on January 3, 2025.

Director Jerome B. Zeldis acquired 4,000 shares of common stock and 8,800 stock options in PTC Therapeutics on January 3, 2025.

Director Glenn Steele Jr. of PTC Therapeutics acquired 4,000 shares of common stock and 8,800 stock options on January 3, 2025.

Director David P. Southwell acquired 4,000 shares and 8,800 stock options in PTC Therapeutics on January 3, 2025, according to a recent SEC filing.

PTC Therapeutics director, Mary L. Smith, acquired 4,000 shares of common stock and 8,800 stock options on January 3, 2025.

Director Emma Reeve of PTC Therapeutics acquired 4,000 shares of common stock and 8,800 stock options on January 3, 2025.

Director Stephanie Okey of PTC Therapeutics acquired 4,000 shares of common stock and 8,800 stock options on January 3, 2025.

Director Allan Steven Jacobson reports acquisition of common stock and stock options in PTC Therapeutics, Inc.

A director of PTC Therapeutics, Michael Schmertzler, acquired 8,000 shares of common stock and 17,600 stock options on January 3, 2025.

Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, reports acquisition of common stock and stock options.

Mark Boulding, Executive VP and CLO of PTC Therapeutics, reports acquiring 18,000 shares of common stock and 45,000 stock options on January 3, 2025.

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, reports acquisition of shares and stock options.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, reports acquisition of shares and stock options.

CEO Eric Pauwels reports acquisition of restricted stock units and stock options in PTC Therapeutics.